AGIOS CLO reports equity awards and tax-share sales
AGIOS PHARMACEUTICALS, INC.
Rhea-AI Filing Summary
AGIOS PHARMACEUTICALS, INC. Chief Legal Officer James William Burns reported multiple equity transactions. On March 1, 2026, he received grants of 14,000 restricted stock units and 52,000 stock options, both vesting over several years beginning March 1, 2027. On March 2, 2026, he exercised previously granted restricted stock units into common shares and reported open-market sales totaling 5,218 common shares at $28.96 per share to cover tax withholding obligations related to performance share vesting. These sales were executed under durable automatic sale instructions consistent with Rule 10b5-1(c). Following these transactions, he directly held 44,086 common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
14 txns
Insider
Burns James William
Role
Chief Legal Officer
Sold
5,218 shs ($151K)
Approx. gross sale proceeds
$151K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted stock units | 4,000 | $0.00 | $0.00 |
| Exercise | Restricted stock units | 5,666 | $0.00 | $0.00 |
| Exercise | Restricted stock units | 4,000 | $0.00 | $0.00 |
| Exercise | Restricted stock units | 3,920 | $0.00 | $0.00 |
| Exercise | Common stock | 4,000 | $0.00 | $0.00 |
| Sale | Common stock | 1,187 | $28.96 | $34K |
| Exercise | Common stock | 5,666 | $0.00 | $0.00 |
| Sale | Common stock | 1,681 | $28.96 | $49K |
| Exercise | Common stock | 4,000 | $0.00 | $0.00 |
| Sale | Common stock | 1,187 | $28.96 | $34K |
| Exercise | Common stock | 3,920 | $0.00 | $0.00 |
| Sale | Common stock | 1,163 | $28.96 | $34K |
| Grant/Award | Restricted stock units | 14,000 | $0.00 | $0.00 |
| Grant/Award | Stock options (right to buy) | 52,000 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted stock units — 35,506 contracts (Direct);
Stock options (right to buy) — 52,000 contracts (Direct);
Common stock — 44,086 shares (Direct)
Footnotes (9)
- F1. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023.
- F2. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024.
- F3. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025.
- F4. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F5. The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments.
- F6. This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- F7. The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.
- F8. The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.
- F9. The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did AGIO Chief Legal Officer James Burns report?
James Burns reported equity awards, option grants, derivative exercises, and tax-related share sales. On March 1–2, 2026, he received new restricted stock units and options, exercised vested units into common stock, and sold shares to satisfy tax withholding tied to performance share vesting.
What new equity awards did James Burns receive from AGIOS PHARMACEUTICALS?
James Burns received 14,000 restricted stock units and 52,000 stock options on March 1, 2026. The RSUs begin vesting in three equal annual installments from March 1, 2027, while the options vest 25% on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments.
What do the restricted stock unit terms for AGIO’s James Burns specify?
Each restricted stock unit represents a contingent right to receive one share of AGIOS common stock. Various RSU grants made in 2023, 2024, 2025, and 2026 vest in three equal annual installments beginning one year after the respective March 1 grant dates, as described in the footnotes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
